Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Nakamura, Yoshio, Kitano, Shigehisa, Takahashi, Akira, Tsutsumida, Arata, Namikawa, Kenjiro, Tanese, Keiji, Abe, Takayuki, Funakoshi, Takeru, Yamamoto, Noboru, Amagai, Masayuki, Yamazaki, Naoya
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363594/
https://ncbi.nlm.nih.gov/pubmed/27764805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12677
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados